These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 20418202)

  • 1. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
    Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
    Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Angiogenesis targeting in renal carcinomas].
    Pouessel D; Culine S
    Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
    Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
    Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
    J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of angiogenesis inhibitors on renal cell carcinoma].
    Bodrogi I
    Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
    Mills EJ; Rachlis B; O'Regan C; Thabane L; Perri D
    BMC Cancer; 2009 Jan; 9():34. PubMed ID: 19173737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
    de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF
    Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
    Chowdhury S; Larkin JM; Gore ME
    Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
    Sire M; Wallerand H; Kilkoski F; Grenier N; Ferrière JM; Ravaud A
    Bull Cancer; 2008 Sep; 95(9):813-20. PubMed ID: 18829413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal cell carcinoma and antiangiogenic therapies].
    Pouessel D; Culine S; Verhoest G; Patard JJ
    Presse Med; 2008 Apr; 37(4 Pt 2):628-33. PubMed ID: 18035517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
    Hutson TE
    Oncologist; 2011; 16 Suppl 2(Suppl 2):14-22. PubMed ID: 21346036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
    Fléchon A; Boyle H; Négrier S
    Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.